1. In Vivo
  2. >>Global Vision

In Search of NeuroSearch

 
• By Chris Morrison

Recent clinical failures have left Denmark's NeuroSearch uncomfortably dependent on NS2330, a promising phase II Alzheimer's and Parkinson's treatment out-licensed to Boehringer Ingelheim. To reduce risk, NeuroSearch will have to partner its remaining research programs earlier.

NeuroSearch AS 's February deal with Germany's Boehringer Ingelheim GMBH for the worldwide development and marketing of its novel Alzheimer's and Parkinson's treatment, NS2330, secured the company a $20 million down-payment and a potential $60 million in milestones [See Deal]. Boehringer will also pay for the rest of NS2330's development, as well as all production and marketing costs, and NeuroSearch will receive double-digit royalties should the drug make it to market. But this transaction—impressive by 2002 dealmaking standards—was important for more than just its financial terms. Coincident with the company's decision to drop three of its most advanced development projects in late 2001 and early 2002, it provided a strong endorsement of the science behind NS2330—and of NeuroSearch's entire ion channel-based discovery engine.

Unexplained toxicology problems in preclinical studies doomed the phase II depression treatment NS2389, which NeuroSearch was developing with GlaxoSmithKline...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By David Wild

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.